Immunohistochemical Evaluation of Vasopressin Expression in Breast Fibrocystic Disease and Ductal Carcinoma in Situ (DCIS)

Endocrine Pathology

Volumn 14, Issue 3, 2003, Pages 257-262

  North, William G ^a   Wells, Wendy ^a   Fay, Michael J ^a   Mathew, Rennie S ^a   Donnelly, Edward M ^a   Memoli, Vincent A ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Breast fibrocystic disease; Ductal carcinoma in situ; Immunohistochemistry; Vasopressin

Indexed keywords

VASOPRESSIN;

ARTICLE; BREAST BIOPSY; BREAST CARCINOMA; BREAST DISEASE; CELL PROLIFERATION; CLINICAL ARTICLE; FEMALE; FIBROCYSTIC BREAST DISEASE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; PRIORITY JOURNAL;

BIOPSY; BREAST NEOPLASMS; CARCINOMA, DUCTAL; FEMALE; FIBROCYSTIC BREAST DISEASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; RETROSPECTIVE STUDIES; VASOPRESSINS;

EID: 0242320292     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1385/EP:14:3:257     Document Type: Article

References (31)

1. Henderson IC. Risk factors for breast cancer development. Cancer 71:2127-2140, 1993.
2. Allred, DC, Mohsin, SK, Fuqua, SA. Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer 8:47-61, 2001.
3. Connolly JL, Schnitt SJ. Benign breast disease resolved and unresolved issues. Cancer 71:1187-1189, 1993.
4. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312:146-151, 1985.
5. Dupont WD, Parl FF, Hartmann WH, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 71:1258-1265, 1993.
6. London SJ, Connolly JL, Schnitt SJ, Colditz GA. A prospective study of benign breast disease and the risk of breast cancer. JAMA 267:941-944, 1992.
7. Mallon E, Osin P, Nasiri N, Blain I, Howard B, Gusterson B. The basic pathology of breast cancer. J. Mammary Gland Biol Neoplasia 5:139-163, 2000.
8. Bai M, Agnantis NJ, Kamina S, et al. In vivo cell kinetic in breast carcinogenesis. Breast Cancer Res 3:276-283, 2001.
9. North WG, Pai S, Friedmann A, Yu X, Fay M, Memoli V. Vasopressin gene related products are markers of human breast cancer. Breast Cancer Res Treatment 34:229-235, 1995.
10. Friedmann AS, Malott KA, Memoli VA, Pai SI, Yu X, North WG. Products of vasopressin gene expression in small-cell carcinoma of the lung. Br J Cancer 69:260-263, 1994.
11. North WG. Neuropeptide production by small cell carcinoma: vasopressin and oxytocin as plasma markers of disease. J Clin Endocrinol Metab 73:1316-1320, 1991.
12. Waddell WJ. A simple ultraviolet spectrophotometric method for the determination of protein. J Lab Clin Med 48:311-314, 1956.
13. Guesdon JL, Ternynck T, Avaremeas S. The use of avidin-biotin interaction in immunoenzymatic techniques. J Histochem Cytochem 27:1131-1139, 1979.
14. Streefkerk JG. Inhibition of erythrocyte pseudoperoxidase activity by treatment with hydrogen peroxide following methanol. J Histochem Cytochem 20:829-831, 1972.
15. Gupta A., Sasarula S, Rao PV. The syndrome of inappropriate secretion of antidiuretic hormone in a case of carcinoma of the breast. J Assoc Physicians India 34:441-442, 1986.
16. Howard AC, Laing RW, Hussain FN. Breast carcinoma presenting with inappropriate ADH secretion. Eur J Cancer 29A:2339, 1993.
17. Guillon G, Kirk CJ, Balestre M. Characterization of specific V1a vasopressin-binding sites on a rat mammary-tumor-cell line. Biochem J 240:189-196, 1986.
18. Kirk CJ, Guillon G, Balestre M, Jard S. Stimulation, by vasopressin and other agonists, of inositol-lipid breakdown and inositol phosphate accumulation in WRK 1 cells. Biochem J 240:197-204, 1986.
19. Monaco ME, Lippman ME, Knazek R, Kidwell WR. Vasopressin stimulation of acetate incorporation into lipids in a dimethylbenz(a)anthracene-induced rat mammary tumor induced cell line. Cancer Res 38:4101-4104, 1978.
20. Monaco ME, Kidwell WR, Lippman ME. Neurohypophysial-hormone-responsive cell line derived from a dimethylbenzanthracene-induced rat mammary tumor. Biochem J 188:437-441, 1980.
21. Woods DJ, Monaco ME. Characterization of the vasopressin receptor on WRK-1 cells. Mol Endocrinol 2:350-354, 1988.
22. Taylor AH, Ang VTY, Jenkins JS, Silverlight JJ, Coombes RC, Luqmani YA. Interaction of vasopressin and oxytocin with human breast carcinoma cells. Cancer Res 50:7882-7886, 1990.
23. Bunn PA, Dienhart DG, Chan D, Tagawa M, Jewett P. Effects of neuropeptides on human lung and breast cancer cells. J Natl Cancer Inst Monogr 13:145-151, 1992.
24. Chooi K, Carter DA, Biswas S, Lightman SL, Ho M, Murphy D. Ectopic vasopressin expression in MMTV-Wnt-1 transgenic mice modifies mammary tumor differentiation and pathology. Cancer Res 54:6434-6440, 1994.
25. Skinner KA, Silverstein MJ. The management of ductal carcinoma of the breast. Endocrin Relat Cancer 8:33-45, 2001.
26. Mokbel K. Current management of ductal carcinoma in situ of the breast. Int J Clin Oncol 8:18-22, 2003.
27. Ariga N, Suzuki T, Moriya T, et al. Progesterone receptor A and B isoforms in the human breast and its disorders. Jpn J Cancer Res 92:302-308, 2001.
28. Winston JS, Asch HL, Zhang PJ, Edge SB, Hyland A, Asch BB. Downregulation of gelsolin correlates with the progression to breast carcinoma. Breast Cancer Res Treat 65:11-21, 2001.
29. Leal C, Henrique R, Monteiro P, et al. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers. Human Path 32:487-493, 2001
30. Suo Z, Bjaamer A, Ottestad L, Nesland JM. Expression of EGFR family and steroid hormone receptors in ductal carcinoma in situ of the breast. Ultrastruct Pathol 25:349-356, 2001.
31. De Paepe B, Verstraeten VL, De Potter CR, Vakaet LA, Bullock GR. Growth stimulatory angiotensin II type-1 receptor is upregulated in breast hyperplasia and in situ carcinoma but not in invasive carcinoma. Histochem Cell Biol 116:247-254, 2001.